The compound should be stored at -20C (or preferably -80C) to maximise long-term stability
In such patients, the ADA-EASD 2022 consensus report also recommends the combination of GLP-1RAs and SGLT2is when hemoglobin A1c (HbA1c) target is not reached with a drug from one of the two classes [6]

The prior authorization requirements when diabetes is present If you have type 2 diabetes and want MassHealth to cover a GLP-1 medication (Ozempic, not Wegovy), the prior authorization pathway requires: Clinical criteria: Documented type 2 diabetes diagnosis (ICD-10 code E11.x) BMI of 27 or higher At least one obesity-related comorbidity: hypertension, dyslipidemia, cardiovascular disease, or sleep apnea HbA1c of 7.0% or higher despite current therapy Trial and inadequate response to metformin for at least 90 days (documented by prescription fill history or provider attestation) Trial and inadequate response to at least one additional oral diabetes medication (sulfonylurea, DPP-4 inhibitor, or SGLT2 inhibitor) for at least 90 days Documentation requirements: Current HbA1c lab result (within 90 days) Current weight and BMI List of prior diabetes medications with dates and reasons for discontinuation or inadequacy Treatment plan including diet and exercise counseling The prior authorization is reviewed by MassHealth's pharmacy benefit manager (currently Gainwell Technologies as of 2026)

Storage and Handling (Laboratory Use Only) Store sealed vials at room temperature (1525C), protected from light
Can I develop Bells Palsy from the vaccine
So lets break it down in therapist language: what it is, what the science actually supports, and why this is going to land in your treatment room more often next year